The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Pemetrexed medac pemetrexed Generic | medac Gesellschaft für klinische Spezialpräparate mbH | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2015-11-26 | Order → |
| Ravicti glycerol phenylbutyrate Orphan | Immedica Pharma AB | Urea Cycle Disorders, Inborn | 🇪🇺 EU 2015-11-26 | Order → |
| Blincyto blinatumomab OrphanAdditional monitoring | Amgen Europe B.V. | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2015-11-23 | Order → |
| Cotellic cobimetinib | Roche Registration GmbH | Melanoma | 🇪🇺 EU 2015-11-20 | Order → |
| Kolbam cholic acid Exceptional circumstances | Retrophin Europe Ltd | Metabolism, Inborn Errors | 🇪🇺 EU 2015-11-20 | Order → |
| Praxbind idarucizumab Accelerated assessment | Boehringer Ingelheim International GmbH | Hemorrhage | 🇪🇺 EU 2015-11-20 | Order → |
| Cinacalcet Viatris (previously Cinacalcet Mylan) cinacalcet Generic | Mylan Pharmaceuticals Limited | Hyperparathyroidism, Secondary; Hypercalcemia | 🇪🇺 EU 2015-11-19 | Order → |
| Entresto sacubitril;valsartan | Novartis Europharm Limited | Heart Failure | 🇪🇺 EU 2015-11-19 | Order → |
| Genvoya elvitegravir;cobicistat;emtricitabine;tenofovir alafenamide | Gilead Sciences Ireland UC | HIV Infections | 🇪🇺 EU 2015-11-19 | Order → |
| Kyprolis carfilzomib Accelerated assessment | Amgen Europe B.V. | Multiple Myeloma | 🇪🇺 EU 2015-11-19 | Order → |
| Numient levodopa;carbidopa | Amneal Pharma Europe Ltd | Parkinson Disease | 🇪🇺 EU 2015-11-19 | Order → |
| Orkambi lumacaftor;ivacaftor | Vertex Pharmaceuticals (Ireland) Limited | Cystic Fibrosis | 🇪🇺 EU 2015-11-19 | Order → |
| Pemetrexed Pfizer (previously Pemetrexed Hospira) pemetrexed Generic | Pfizer Europe MA EEIG | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2015-11-19 | Order → |
| Elocta efmoroctocog alfa | Swedish Orphan Biovitrum AB (publ) | Hemophilia A | 🇪🇺 EU 2015-11-18 | Order → |
| Ionsys fentanyl | Incline Therapeutics Europe Ltd | Pain, Postoperative | 🇪🇺 EU 2015-11-18 | Order → |
| Aripiprazole Accord aripiprazole Generic | Accord Healthcare S.L.U. | Schizophrenia; Bipolar Disorder | 🇪🇺 EU 2015-11-15 | Order → |
| Ebymect dapagliflozin;metformin | AstraZeneca AB | Diabetes Mellitus, Type 2 | 🇪🇺 EU 2015-11-15 | Order → |
| Obizur susoctocog alfa Exceptional circumstancesAdditional monitoring | Baxalta Innovations GmbH | Hemophilia A | 🇪🇺 EU 2015-11-11 | Order → |
| Edistride dapagliflozin | AstraZeneca AB | Diabetes Mellitus, Type 2; Heart Failure, Systolic; Heart Failure; Renal Insufficiency, Chronic | 🇪🇺 EU 2015-11-09 | Order → |
| Cresemba isavuconazole Orphan | Basilea Pharmaceutica Deutschland GmbH | Aspergillosis | 🇪🇺 EU 2015-10-15 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.